Strategic Partnerships CHDI Foundation actively collaborates with academic and industrial scientists and engages with external organizations through CHDI Management, presenting a strong foundation for co-development, joint research initiatives, and potential sponsored projects with pharma, biotech, and contract research organizations.

Biomarker Innovation Recent and ongoing work includes tracer development for Huntington's disease and precision eye movement biomarkers, offering sales opportunities in biomarker assay development, imaging endpoints, and companion diagnostic services for clinical trials.

Technology Enablement Dependence on digital tools and platforms (iCIMS, Power Platform, SharePoint, Intune, Active Directory, Cisco) indicates openness to technology partnerships, data management solutions, security-compliant collaboration platforms, and custom software or integration services to support research programs.

Nonprofit Research Model As a non-profit foundation with significant revenue in the mid-range and a global collaboration network, CHDI may pursue grant-aligned or value-driven partnerships, potentially open to sponsored research, milestone-based collaborations, and shared-IP arrangements with industry partners.

Clinical Endpoints Focus Investments in translational biology leadership and novel endpoints for trials (e.g., biomarkers, predictive models) signal opportunities to offer translational science services, endpoint validation, data analytics, and late-stage trial support to accelerate HD therapeutic programs.